Lv3
268 积分 2024-05-22 加入
Assessment of the Immunogenicity Potential for Oligonucleotide-Based Drugs
8天前
已完结
Zerlasiran—A Small-Interfering RNA Targeting Lipoprotein(a)
15天前
已完结
Lepodisiran — A Long-Duration Small Interfering RNA Targeting Lipoprotein(a)
15天前
已完结
Lepodisiran — A Long-Duration Small Interfering RNA Targeting Lipoprotein(a)
15天前
已完结
Comparison of Child-Pugh (CP) criteria and NCI organ dysfunction working group (NCI-ODWG) criteria for hepatic dysfunction (HD): Implications for chemotherapy dosing
15天前
已关闭
Olpasiran lowering of lipoprotein(a) according to baseline levels: insights from the OCEAN(a)-DOSE study
15天前
已完结
Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)
15天前
已完结
Olpasiran, Oxidized Phospholipids, and Systemic Inflammatory Biomarkers
15天前
已完结
Safety and efficacy of once-daily HU6 versus placebo in people with non-alcoholic fatty liver disease and high BMI: a randomised, double-blind, placebo-controlled, phase 2a trial
1个月前
已完结
Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial
1个月前
已完结
皖公网安备34019202002308
